30 November 2020: Clinical Research
Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
Chang Liu 12CDEF* , Ting Li 12CDEF* , Zhonghua Tao 12B , Jun Cao 12B , Leiping Wang 12B , Jian Zhang 12B , Biyun Wang 12A* , Xichun Hu 12A*DOI: 10.12659/MSM.927187
Med Sci Monit 2020; 26:e927187
Table 3 Efficacy of palbociclib-based treatment in different treatment-line settings.
| Characteristic | All patients | 1st line | ≥2nd line | ≥4th line |
|---|---|---|---|---|
| Best response, n (%) | ||||
| CR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| PR | 14 (11.3%) | 12 (30.8%) | 2 (2.4%) | 0 (0.0%) |
| SD | 82 (66.1%) | 24 (61.5%) | 58 (68.2%) | 12 (66.7%) |
| PD | 28 (22.6%) | 3 (7.7%) | 25 (29.4%) | 6 (33.3%) |
| DCR | 77.4% | 92.3% | 70.6% | 66.7% |
| CBR | 63.4% | 78.9% | 56.5% | 44.4% |
| Median PFS, months | 9.2 | 14.7 | 7.4 | 4.4 |
| Median follow-up period, months | 10.6 | 10.6 | 11.0 | 10.4 |
| CR – complete response; PR – partial response; SD – stable disease; PD – progression of disease; ORR – objective response rate; DCR – disease control rate; CBR – clinical benefit rate; SD – standard deviation. | ||||